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Hepatitis C virus (HCV) contains a highly variable RNA ge-
nome with up to 35% differences in the nucleotide sequence.
Phylogenetic analyses of nucleotide sequences of the genome
of HCV revealed six different types and even more subtypes of
this virus. These analyses also showed that variability of the
HCV genome is not uniform. To be specific, the nontranslating
ends [5’non-translated region (NTR) and 3’NTR], which have a
regulatory role in transcription and replication of the virus, are
conservative (V a n  L e e u w e n, 2004; S i m m o n d s,
2004). Contrary to that, so-called hypervariable regions (HVR1
and HVR2), which encode the main antigenic determinants, oc-
cur in the envelope protein gene of this virus (S m i t h et al.,
1995; S i m m o n d s, 2004). Due to the existence of HVR, a
persistent immune response is obstructed in HCV infection,
which leads to a chronic condition that can develop into cirrho-
sis and hepatocellular carcinoma. However, early stages of in-
fection are most often with a sub-clinical picture, because HCV
is believed to be noncytopathic and hepatitis is mediated by host
immune responses (F a g a n and H a r r i s o n, 2000; S i m -
m o n d s, 2004). 
In rare cases, HCV can be detected in persons with fulmi-
nant hepatitis (FH), the most severe form of acute hepatitis,
characterized by massive hepatocyte necrosis, development of
hepatic encephalopathy, and high mortality. In cases of FH with
HCV infection, the most frequent additional conditions are:
hepatitis B virus co-infection, immune suppression, hematolog-
ical disease, conditions requiring or chemotherapy (F a g a n
and H a r r i s o n, 2000). Some results obtained for FH with
HCV infection (FHC) without additional risk factors indicate
that the characteristics of viral isolates can influence the patho-
genesis of this disease. F a r c i et al. (1999) inoculated virus
isolated from a patient with FHC into a chimpanzee, which in-
duced an unexpectedly severe form of FHC. In addition, K a t o
et al. (2001) compared the complete nucleotide sequence of the
HCV isolate from a patient with FHC with six viral isolates
from patients with chronic hepatitis C of the same 2a genotype.
The greatest diversity was found in 5’NTR, although this is the
most conservative region in the HCV genome. The authors con-
cluded that the influence of the nucleotide structure of 5’NTR
on virus replication and translation of virus proteins could be
crucial in the development of fulminant hepatitis (K a t o et al.,
2001).
In this study, we analyzed the genome of HCV isolate from
a patient with FHC and compared the 5’NTR with other isolates
of the same genotype from patients with chronic hepatitis C in
Serbia.
A 59-year-old female patient underwent resection and re-
construction of an abdominal aneurism with graft interposition
in 2001. The procedure and the postoperative period had no
complications. Before this, liver function and serologic marker
tests (for HCV, HBV and HIV) were normal. Alcohol abuse, he-
patotoxic drugs, and hypoxia were also excluded. During the
second postoperative week, the patient suffered from loss of ap-
petite, nausea, vomiting and fatigue. Marked elevation of ala-
nine aminotranferase (ALT = 2919 U/L, normal <40 U/L), hy-
perbilirubinemia (total bilirubin = 366 μmol/L, normal <17 μm-
ol/L), and coagulopathy (prothrombin time = 60 s, normal 15 s)
were noticed during the first laboratory check, on the 10th day
of illness. During the second week, the icterus progressed, and
hepatic encephalopathy with marked somnolence and severely
disturbed verbal responses developed. On day 17 of the illness,
the amount of HCV RNA was 105 copies/mL, as detected by a
commercial PCR test (Cobas Amplicor HCV Monitor tests, Ro-
che Diagnostic Systems, Mannheim, Germany). The appear-
ance of anti-HCV antibody (seroconversion) happened after
day 20. The PCR test then showed a drop of viremy by one lev-
el of magnitude and 1 week after that viremy had became unde-
tectable (Fig. 1).
The patient recovered completely within 3 months. The
most important survival predictor in FH without liver transplan-
tation is the hepatic encephalopathy grade (65% with encepha-
lopathy I and II survive and 20% with encephalopathy III and
IV). Other predictive factors for poor prognosis are age (young-
er than 10 years and older than 40 years), the level of total bili-
rubin (>300 μmol/L), hyperbilirubinemia lasting more than 7
days before the occurrence of hepatic encephalopathy, and a
prolonged prothrombin time (>50 s) (S h e r l o c k and D o o -
l e y, 2002). Our patient developed grade II hepatic encephalop-
athy and the prior duration of hyperbilirubinemia was less than
7 days, which were favorable prognostic factors. However, age,
bilirubin concentration and coagulopathy were poor prognostic
factors.
We compared the 5’NTR nucleotide sequence of HCV iso-
lates from this FHC patient with the 5’NTR nucleotide sequen-
ces of ten other isolates obtained from patients with chronic
HCV infection in Serbia (Blast research program). Briefly, the
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HCV genome was isolated with TRIzolTM-reagent (Gibco-BRL,
Life Technologies). The 5’NTR amplicon, 319 bp in length, was
obtained with a One Step RT-PCR Kit (QIAGEN GmbH, Ger-
many) according to the manufacturer’s instructions and a uni-
versal HCV primer (V i l l a m i l et al., 1995). Automated gene
sequencing of the 5’NTR of the HCV genome was done using
Big Dye ver.3.1 (MWG DNA Biotech Company, Germany).
The 5’NTR sequence of the isolate from our patient was
the same as the prototype of 1b genotype HCV J4 (D10750).
Identical nucleotide sequences were found in eight cases ob-
tained from patients with chronic hepatitis C, while two isolates
showed a C®T (204 nt) nucleotide substitution. Within this
same subtype, the nucleotide sequence of 5’NTR was different
in 1 to 5% of nucleotides.  Besides the change (C®T) at 204 nt
detected here, nucleotide substitutions G®A at 243 nt, C®A at
204 nt, C®T at 120 nt, etc. have been recorded in different iso-
lates of subtype 1b from subjects affected by chronic hepatitis
C (B u k h et al., 1992; S m i t h et al., 1995; S t a m e n k o v -
i ć et al., 2001). It can therefore be said that the examined iso-
late has an almost identical nucleotide sequence of 5’NTR-a as
isolates of the same subtype from 10 chronic carriers of infec-
tion.
In HCV certain differences in the nature and development
of disease have been detected between different genotypes.
However, on the basis of the unclear currently available results
it is difficult to decide if these differences should be included in
the pathogenesis of fulminant hepatitis. Patients infected with
different viral genotypes (1a, 1b, 2a) have developed FHC
(F a r c i et al., 1996, 1999; K a t o et al., 2001). These differ-
ences could be due to worldwide differences in the distribution
of genotypes. The HCV isolate from our patient was the 1b gen-
otype, which is the most common genotype in our country with
49% frequency (S t a m e n k o v i ć et al., 2000).
During the period of the severe form of illness, when he-
patic encephalopathy grade II developed, the viral load was 105
copies/mL (Fig. 1). However, in chronic forms of HCV infec-
tion the viral load is most often from 105 to 107copies/mL,
which means that the number of HCV copies in the blood plas-
ma of our patient was within the range established for chronic
carriers of HCV infection (F a g a n and H a r r i s o n, 2000).
Besides characteristics of the HCV isolate, the route of in-
fection and/or physiological state of postoperative trauma can
also influence the development of FHC (W o o d f i e l d, 1991;
S a c h e r and M e l p o l d e r, 1991; F a r c i et al., 1996).
Most probably, our patient was infected with HCV via blood
transfusions received during the surgery because the blood
pools were tested for anti-HCV antibody, but the presence of
HCV RNA was not tested by PCR which can detect HCV RNA
in infected blood donors many weeks before appearance of the
antibody (H i t z l e r and R u n k e l, 2001). However, the way
in which the pattern of infection can influence the development
and progress of the disease is not completely clear, even though
it has been established that severe forms of it develop most fre-
quently after virus transfer in transfusions (W o o d f i e l d,
1991; F a g a n and H a r r i s o n, 2000).
It can be concluded that HCV can be the sole cause of ful-
minant hepatitis. The 5’NTR in the HCV isolate obtained from
our patient had the same nucleotide sequence as the majority of
isolates of this virus from the plasma of patients with chronic
hepatitis. The importance of particular isolates, HCV geno-
types, and/or viral load can be determined only after studying
more patients with FHC and after comparative analyses of the
complete nucleotide sequence, which is the aim of our further
studies.
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Fig. 1. Biochemical, serological, and molecular profiles of fulminant
hepatitis C in the infected patient. The results were obtained 10 days
after the first symptoms (ALT - alanine aminotranferase, T.Bil.- total
bilirubin, PT - prothrombin time).
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